Are antibiotic-resistant superbugs more fatal than COVID-19?

January 15, 2021 12:04 AM EST | By Edita Ivancevic
 Are antibiotic-resistant superbugs more fatal than COVID-19?

Image Source: Shutterstock

Summary

  • While COVID-19 is still killing many people across the world, antibiotics resistance could take more than 10 million lives by 2050 if scientists do not come up with a successful solution.
  • So far, parts of Eastern Europe and the US are trying intravenous bacteriophage treatments, as those organisms kill viruses by injecting their own DNA in dangerous microorganisms.
  • Some researchers in Australia are optimistic about the therapy’s future, as some patients showed miraculous recovery after just a few weeks of trials.

Ever since coronavirus affected the first human being and caused the first fatal case, scientists have put their entire focus on combatting the novel virus.

However, many diseases that were troubling and concerning, even before COVID-19 killed almost two million people globally, did not get as much attention as coronavirus or funds to find a proper solution.

Some of those health issues are -- undestroyable microorganisms and superbugs. They are dangerous as they develop antibiotic resistance to standard medicines.

Some experts forecast that more than 10 million people will likely die due to antibiotic resistance by 2050. For that reason, many are trying to find a long-term solution for fighting against microbiomes, which are immune to modern medicines.

However, a couple of Australian scientists are optimistic that human waste could be the key to fight the lurking problem.

Humans naturally eject bacteriophages through sewage, organisms that find germs inside the body and kill them by injecting their DNA into the problematic virus.

Resistance to most common medicine is already affecting specific individuals, specifically people from the older generation, who take at least one pill per day and who got overly prescribed for antibiotics.

That said, scientists thought of a possible solution some patients could follow when things go south – phage treatments.

Bacteriophages could be easily extracted from human faeces and urine, so Dr Ruby Lin and Dr Khalid believe sewage phage could be a miracle treatment:

Almost 300 people living in Australia die each year due to virus infections that cannot be cured with regular drugs, according to the Organisation for Economic Cooperation and Development (OECD).

Australian Commission of Safety and Quality in Healthcare reported that doctors are prescribing too many antibiotics and that many people are misusing the drugs in question. Those factors resulted in a significant problem and created superbugs, organisms that are immune to almost all medical treatments.

What are some case studies involving bacteriophage treatment?

Dr Lin is part of the team at the Westmead Institute for Medical Research (WIMR), which is running clinical trials on certain individuals facing a superbug infection.

Currently, there are 13 patients that are testing the phage therapy. One of them is a little girl who developed severe disease in her leg after meeting a car accident overseas.

After the girl and her doctors realised that the leg was not healing properly, the girl was sent to the Institute so that the superbug could be thoroughly investigated.

The WIMR Professor Jon Iredell was the researcher looking into the little girl’s case, and has observed the following:

After weeks of careful observation and identifying the exact superbug, the little girl fully recovered and started walking properly.

What is the biggest challenge during the therapy?

According to experts, the time before they identify which bacteriophage is to be used for a specific infection is the key factor, as the superbug could kill the host in the meantime if not successfully contained.

But, finding the correct phage is also a challenge, as different phage DNAs kill different viruses. Essentially, there is no universal bacteriophage for several infections.

The treatment had still not been thoroughly investigated, but scientists think it could be a world-changer for specific patients that have already drained their possibilities.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.